Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors

OBJECTIVES: Patients with non-small-cell lung cancer (NSCLC) develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) after tumor regression. No approved targeted therapies are currently available after initial EGFR TKI treatment. This study investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qi, Quan, Qi, Ding, Lingyu, Hong, Xiangchan, Zhou, Ningning, Liang, Ying, Wu, Haiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694802/
https://www.ncbi.nlm.nih.gov/pubmed/26172562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694802/
https://www.ncbi.nlm.nih.gov/pubmed/26172562

Ejemplares similares